All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Phase III SELENE trial: efficacy and safety of ibrutinib plus BR/R-CHOP in R/R FL or MZL
Here, we summarize key efficacy and safety data from the randomized phase III SELENE trial investigating ibrutinib plus BR or R-CHOP compared with placebo in...
FDA approves pirtobrutinib for patients with relapsed/refractory CLL/SLL
Pirtobrutinib has been approved by the U.S. FDA for the treatment of patients with relapsed/refractory CLL or SLL, based on results from the phase I/II BRUIN trial.
Your opinion matters